KC
Keith Crandell
10% Owner
Keith Crandell10% Owner
Keith Crandell insider trades: Lyell Immunopharma (LYEL) stock buys and sales
10% Owner, Lyell Immunopharma Last trade Nov 4, 2026 156 Form 4 filings
$40K
Sold, last 12 months
1 sale
$100.4M
Bought, last 12 months
7 buys
56
Open-market trades
since 2006
49
Companies
last trade 2026
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Keith reports to the SEC
LYELLyell Immunopharma
10% Owner · last filing Nov 5, 2026
+$37.5M
ASPEAspen Neuroscience
Insider · last filing Nov 2, 2026
+$20.0M
CTYCity Therapeutics
10% Owner · last filing Oct 19, 2026
+$3.1M
BOLDBoundless Bio
10% Owner · last filing Jul 6, 2026
-$40K
+$3.2M
KARDKardigan
Director · last filing Jun 24, 2026
+$20.0M
SPTXSeaport Therapeutics
Insider · last filing May 4, 2026
+$19.8M
and 43 more companies
Open-market buys and sales
56 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | LYEL | ↑ Buy | 2,321,262 | $10.77 | $25.0M | Indirect | Nov 5, 2026 (1d) |
| Nov 2, 2026 | ASPE | ↑ Buy | 1,200,000 | $15.00 | $18.0M | Indirect | Nov 2, 2026 (0d) |
| Nov 2, 2026 | ASPE | ↑ Buy | 133,333 | $15.00 | $2.0M | Direct | Nov 2, 2026 (0d) |
| Oct 19, 2026 | CTY | ↑ Buy | 170,000 | $18.00 | $3.1M | By ARCH Venture Fund XII, L.P. | Oct 19, 2026 (0d) |
| Jul 1, 2026 | BOLD | ↓ Sell | 16,000 | $2.49 | $40K | Indirect | Jul 6, 2026 (5d) |
| Jun 22, 2026 | KARD | ↑ Buy | 1,250,000 | $16.00 | $20.0M | By: ARCH Venture Fund XIII, L.P. | Jun 24, 2026 (2d) |
| May 4, 2026 | SPTX | ↑ Buy | 1,100,000 | $18.00 | $19.8M | By ARCH Venture Fund XII, L.P. | May 4, 2026 (0d) |
| Mar 6, 2026 | LYEL | ↑ Buy | 488,090 | $25.61 | $12.5M | Indirect | Mar 9, 2026 (3d) |
| Oct 27, 2025 | NMRA | ↑ Buy | 1,915,700 | $2.61 | $5.0M | By ARCH Venture Fund XII, L.P. | Oct 29, 2025 (2d) |
| Aug 1, 2025 | PRME | ↑ Buy | 3,030,300 | $3.30 | $10.0M | By ARCH Venture Fund XII, L.P. | Aug 1, 2025 (0d) |
| Feb 3, 2025 | MTSR | ↑ Buy | 2,222,222 | $18.00 | $40.0M | Indirect | Feb 3, 2025 (0d) |
| Apr 2, 2024 | BOLD | ↑ Buy | 200,000 | $16.00 | $3.2M | Indirect | Apr 4, 2024 (2d) |
| Feb 15, 2024 | PRME | ↑ Buy | 3,200,000 | $6.25 | $20.0M | By ARCH Venture Fund XII, L.P. | Feb 20, 2024 (5d) |
| Feb 8, 2024 | SANA | ↑ Buy | 1,090,909 | $5.50 | $6.0M | Indirect | Feb 12, 2024 (4d) |
| Nov 14, 2023 | NMRA | ↑ Buy | 35,010 | $11.77 | $412K | By ARCH Venture Fund XII, L.P. | Nov 15, 2023 (1d) |
| Nov 10, 2023 | NMRA | ↑ Buy | 140,605 | $10.98 | $1.5M | By ARCH Venture Fund XII, L.P. | Nov 13, 2023 (3d) |
| Nov 7, 2023 | NMRA | ↑ Buy | 95,694 | $11.49 | $1.1M | By ARCH Venture Fund XII, L.P. | Nov 7, 2023 (0d) |
| Sep 29, 2023 | NMRA | ↑ Buy | 76,511 | $13.68 | $1.0M | By ARCH Venture Fund XII, L.P. | Sep 29, 2023 (0d) |
| Sep 27, 2023 | NMRA | ↑ Buy | 58,504 | $11.97 | $700K | By ARCH Venture Fund XII, L.P. | Sep 27, 2023 (0d) |
| Sep 25, 2023 | NMRA | ↑ Buy | 100,740 | $11.19 | $1.1M | By ARCH Venture Fund XII, L.P. | Sep 25, 2023 (0d) |
| Sep 19, 2023 | NMRA | ↑ Buy | 1,500,000 | $17.00 | $25.5M | By ARCH Venture Fund XII, L.P. | Sep 20, 2023 (1d) |
| Oct 24, 2022 | PRME | ↑ Buy | 400,000 | $17.00 | $6.8M | By ARCH Venture Fund X, L.P. | Oct 26, 2022 (2d) |
| Oct 24, 2022 | PRME | ↑ Buy | 400,000 | $17.00 | $6.8M | By ARCH Venture Fund X Overage, L.P. | Oct 26, 2022 (2d) |
| Sep 13, 2022 | CDAK | ↑ Buy | 5,000,000 | $1.50 | $7.5M | Indirect | Sep 15, 2022 (2d) |
| Aug 12, 2021 | TWST | ↓ Sell | 43,588 | $107.01 | $4.7M | By Keith L. Crandell Trust | Aug 13, 2021 (1d) |
| Aug 12, 2021 | TWST | ↓ Sell | 1,412 | $106.93 | $151K | Direct | Aug 13, 2021 (1d) |
| Jul 30, 2021 | DALS | ↑ Buy | 1,600,000 | $10.00 | $16.0M | Through ARCH Venture Fund XI, L.P. | Aug 3, 2021 (4d) |
| Dec 22, 2020 | MASS | ↑ Buy | 300,000 | $20.00 | $6.0M | Indirect | Dec 22, 2020 (0d) |
| Dec 7, 2020 | TWST | ↓ Sell | 53,712 | $103.40 | $5.6M | By Arch Venture Fund VII, L.P. | Dec 9, 2020 (2d) |
| Dec 7, 2020 | TWST | ↓ Sell | 21,288 | $103.40 | $2.2M | By ARCH Venture Fund VIII Overage, L.P. | Dec 9, 2020 (2d) |
| Oct 16, 2020 | CDAK | ↑ Buy | 235,000 | $15.00 | $3.5M | Indirect | Oct 20, 2020 (4d) |
| Sep 18, 2020 | MTCR | ↑ Buy | 230,000 | $13.00 | $3.0M | Indirect | Sep 22, 2020 (4d) |
| Oct 16, 2019 | VIR | ↑ Buy | 1,000,000 | $20.00 | $20.0M | Indirect | Oct 18, 2019 (2d) |
| Jul 17, 2019 | SYRS | ↓ Sell | 63,000 | $7.77 | $489K | Direct | Jul 17, 2019 (0d) |
| Jul 2, 2019 | KRTX | ↑ Buy | 100,000 | $16.00 | $1.6M | Indirect | Jul 2, 2019 (0d) |
| Mar 14, 2019 | SYRS | ↓ Sell | 167,503 | $7.83 | $1.3M | Direct | Mar 14, 2019 (0d) |
| Mar 11, 2019 | SYRS | ↓ Sell | 164,583 | $6.80 | $1.1M | Direct | Mar 11, 2019 (0d) |
| Feb 22, 2019 | SNNA | ↑ Buy | 2,165,800 | $2.50 | $5.4M | Indirect | Feb 26, 2019 (4d) |
| Feb 22, 2019 | SNNA | ↑ Buy | 2,165,800 | $2.50 | $5.4M | Indirect | Feb 26, 2019 (4d) |
| Nov 2, 2018 | TWST | ↑ Buy | 75,000 | $14.00 | $1.1M | Indirect | Nov 6, 2018 (4d) |
| Dec 11, 2017 | QTRX | ↑ Buy | 266,000 | $15.00 | $4.0M | Held by ARCH Venture Fund VIII Overage, | Dec 13, 2017 (2d) |
| Jul 6, 2016 | SYRS | ↑ Buy | 400,000 | $12.50 | $5.0M | Direct | Jul 7, 2016 (1d) |
| May 23, 2016 | PZRX | ↑ Buy | 1,000,000 | $5.00 | $5.0M | By ARCH Venture Fund VII, L.P. | May 25, 2016 (2d) |
| May 23, 2016 | PZRX | ↓ Sell | 680,059 | $0.01 | $7K | By ARCH Venture Fund VII, L.P. | May 25, 2016 (2d) |
| Nov 17, 2015 | XCOM | ↑ Buy | 300,000 | $5.00 | $1.5M | By ARCH Venture Fund VI, L.P. | Nov 18, 2015 (1d) |
| Oct 26, 2015 | IOTS | ↑ Buy | 400,000 | $5.00 | $2.0M | Indirect | Oct 28, 2015 (2d) |
| Oct 26, 2015 | IOTS | ↑ Buy | 400,000 | $5.00 | $2.0M | Direct | Oct 28, 2015 (2d) |
| Jun 16, 2015 | PULM | ↑ Buy | 72,750 | $6.88 | $500K | Indirect | Jun 17, 2015 (1d) |
| Feb 19, 2015 | BLPH | ↑ Buy | 212,666 | $12.00 | $2.6M | Direct | Feb 23, 2015 (4d) |
| May 14, 2014 | RCPT | ↓ Sell | 45,381 | $29.66 | $1.3M | Direct | May 15, 2014 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LYEL insiders
Open-market trades in the last 12 months
ARCH Venture Fund XIII, L.P.
10% Owner
2 buys
Nov 4, 2026
ARCH Venture Partners XIII, LLC
10% Owner
2 buys
Nov 4, 2026
Paul L Berns
10% Owner
2 buys
Nov 4, 2026
Robert Nelsen
10% Owner
2 buys
Nov 4, 2026
Kristina Burow
10% Owner
2 buys
Nov 4, 2026
Clinton Bybee
10% Owner
2 buys
Nov 4, 2026
Steven Gillis
10% Owner
2 buys
Nov 4, 2026
ARCH Venture Partners XIII, L.P.
10% Owner
2 buys
Nov 4, 2026
About Keith Crandell's insider trades
Keith Crandell is a 10% owner of Lyell Immunopharma (LYEL). Since Oct 17, 2006, Keith has reported 46 open-market purchases worth $338.9M and 10 sales worth $16.9M on SEC Form 4. In the last 12 months: 7 buys ($100.4M) and 1 sale ($40K).
Their filings also include grants and awards (46 filings), other transactions (46 filings), conversions (41 filings), option exercises (10 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LYEL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.